Autologous Anti-CD19 CAR-expressing T-lymphocytes therapy(Mayo Clinic)

N/A

Report date: 2024/07/24 20:00:37

Base Information

Drug NameAutologous Anti-CD19 CAR-expressing T-lymphocytes therapy(Mayo Clinic)
Drug Alias NameIC19/1563
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesMayo Clinic
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A